This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kenny, G. E.
Right arrow Articles by Cartwright, F. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kenny, G. E.
Right arrow Articles by Cartwright, F. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2001, p. 2604-2608, Vol. 45, No. 9
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.9.2604-2608.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, Dalfopristin, Dirithromycin, Evernimicin, Gatifloxacin, Linezolid, Moxifloxacin, Quinupristin-Dalfopristin, and Telithromycin Compared to Their Susceptibilities to Reference Macrolides, Tetracyclines, and Quinolones

George E. Kenny* and Frank D. Cartwright

Department of Pathobiology, School of Public Health and Community Medicine, University of Washington, Seattle, Washington 98195

Received 30 January 2001/Returned for modification 2 March 2001/Accepted 31 May 2001

The susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to eight new antimicrobial agents were determined by agar dilution. M. pneumoniae was susceptible to the new glycylcycline GAR-936 at 0.12 µg/ml and evernimicin at 4 µg/ml, but it was resistant to linezolid. It was most susceptible to dirithromycin, quinupristin-dalfopristin, telithromycin, reference macrolides, and josamycin. M. hominis was susceptible to linezolid, evernimicin, and GAR-936. It was resistant to macrolides and the ketolide telithromycin but susceptible to quinupristin-dalfopristin and josamycin. U. urealyticum was susceptible to evernimicin (8 to 16 µg/ml) and resistant to linezolid. It was less susceptible to GAR-936 (4.0 µg/ml) than to tetracycline (0.5 µg/ml). Telithromycin and quinupristin-dalfopristin were the most active agents against ureaplasmas (0.06 µg/ml). The new quinolone gatifloxacin was active against M. pneumoniae and M. hominis at 0.12 to 0.25 µg/ml and active against ureaplasmas at 1.0 µg/ml. The MICs of macrolides were markedly affected by pH, with an 8- to 32-fold increase in the susceptibility of M. pneumoniae as the pH increased from 6.9 to 7.8. A similar increase in susceptibility with increasing pH was also observed with ureaplasmas. Tetracyclines showed a fourfold increase of activity as the pH decreased 1 U, whereas GAR-936 showed a fourfold decrease in activity with a decrease in pH.

* Corresponding author. Mailing address: Department of Pathobiology, Box 357238, University of Washington, Seattle, WA 98195. Phone: (206) 543-1036. Fax: (206) 543-3873. E-mail: kennyg{at}u.washington.edu.

Antimicrobial Agents and Chemotherapy, September 2001, p. 2604-2608, Vol. 45, No. 9
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.9.2604-2608.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Salvatore, C. M., Techasaensiri, C., Tagliabue, C., Katz, K., Leos, N., Gomez, A. M., McCracken, G. H., Hardy, R. D. (2009). Tigecycline Therapy Significantly Reduces the Concentrations of Inflammatory Pulmonary Cytokines and Chemokines in a Murine Model of Mycoplasma pneumoniae Pneumonia. Antimicrob. Agents Chemother. 53: 1546-1551 [Abstract] [Full Text]  
  • Garcia-Castillo, M., Morosini, M.-I., Galvez, M., Baquero, F., del Campo, R., Meseguer, M.-A. (2008). Differences in biofilm development and antibiotic susceptibility among clinical Ureaplasma urealyticum and Ureaplasma parvum isolates. J Antimicrob Chemother 62: 1027-1030 [Abstract] [Full Text]  
  • Waites, K. B., Crabb, D. M., Duffy, L. B. (2008). Comparative In Vitro Activities of the Investigational Fluoroquinolone DC-159a and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. Antimicrob. Agents Chemother. 52: 3776-3778 [Abstract] [Full Text]  
  • Yamazaki, T., Sasaki, T., Takahata, M. (2007). Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 51: 2278-2279 [Full Text]  
  • Izdebski, R., Sadowy, E., Fiett, J., Grzesiowski, P., Gniadkowski, M., Hryniewicz, W. (2007). Clonal Diversity and Resistance Mechanisms in Tetracycline-Nonsusceptible Streptococcus pneumoniae Isolates in Poland. Antimicrob. Agents Chemother. 51: 1155-1163 [Abstract] [Full Text]  
  • Van Wart, S. A., Owen, J. S., Ludwig, E. A., Meagher, A. K., Korth-Bradley, J. M., Cirincione, B. B. (2006). Population Pharmacokinetics of Tigecycline in Patients with Complicated Intra-Abdominal or Skin and Skin Structure Infections. Antimicrob. Agents Chemother. 50: 3701-3707 [Abstract] [Full Text]  
  • Kasbekar, N. (2006). Tigecycline: A new glycylcycline antimicrobial agent.. Am J Health Syst Pharm 63: 1235-1243 [Abstract] [Full Text]  
  • Bradford, P. A., Petersen, P. J., Young, M., Jones, C. H., Tischler, M., O'Connell, J. (2005). Tigecycline MIC Testing by Broth Dilution Requires Use of Fresh Medium or Addition of the Biocatalytic Oxygen-Reducing Reagent Oxyrase To Standardize the Test Method. Antimicrob. Agents Chemother. 49: 3903-3909 [Abstract] [Full Text]  
  • Pankey, G. A. (2005). Tigecycline. J Antimicrob Chemother 56: 470-480 [Abstract] [Full Text]  
  • Waites, K. B., Talkington, D. F. (2004). Mycoplasma pneumoniae and Its Role as a Human Pathogen. Clin. Microbiol. Rev. 17: 697-728 [Abstract] [Full Text]  
  • Pereyre, S., Renaudin, H., Bebear, C., Bebear, C. M. (2004). In Vitro Activities of the Newer Quinolones Garenoxacin, Gatifloxacin, and Gemifloxacin against Human Mycoplasmas. Antimicrob. Agents Chemother. 48: 3165-3168 [Abstract] [Full Text]  
  • Waites, K. B., Crabb, D. M., Duffy, L. B. (2003). Comparative In Vitro Susceptibilities and Bactericidal Activities of Investigational Fluoroquinolone ABT-492 and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. Antimicrob. Agents Chemother. 47: 3973-3975 [Abstract] [Full Text]  
  • Duffy, L. B., Crabb, D. M., Bing, X., Waites, K. B. (2003). Bactericidal activity of levofloxacin against Mycoplasma pneumoniae. J Antimicrob Chemother 52: 527-528 [Full Text]  
  • Neumayr, L., Lennette, E., Kelly, D., Earles, A., Embury, S., Groncy, P., Grossi, M., Grover, R., McMahon, L., Swerdlow, P., Waldron, P., Vichinsky, E. (2003). Mycoplasma Disease and Acute Chest Syndrome in Sickle Cell Disease. Pediatrics 112: 87-95 [Abstract] [Full Text]  
  • Waites, K. B., Crabb, D. M., Duffy, L. B. (2003). In Vitro Activities of ABT-773 and Other Antimicrobials against Human Mycoplasmas. Antimicrob. Agents Chemother. 47: 39-42 [Abstract] [Full Text]  
  • Waites, K. B., Crabb, D. M., Bing, X., Duffy, L. B. (2003). In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. Antimicrob. Agents Chemother. 47: 161-165 [Abstract] [Full Text]  
  • Milatovic, D., Schmitz, F.-J., Verhoef, J., Fluit, A. C. (2003). Activities of the Glycylcycline Tigecycline (GAR-936) against 1,924 Recent European Clinical Bacterial Isolates. Antimicrob. Agents Chemother. 47: 400-404 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»